Ionis Pharmaceuticals (IONS) Current Assets (2009 - 2026)

Ionis Pharmaceuticals' Current Assets history runs 18 years deep, the most recent figure standing at $2.9 billion for Q1 2026.

• On a quarterly basis, Current Assets rose 21.41% year-over-year to $2.9 billion in Q1 2026; TTM through Mar 2026 was $2.9 billion, a 21.41% increase from a year earlier, with the FY2025 full-year figure at $3.0 billion, up 14.13% from the prior year.
• Current Assets retreated to $2.9 billion in Q1 2026 per IONS's latest filing, from $3.0 billion in the prior quarter.
• Across five years, Current Assets topped out at $3.0 billion in Q4 2025 and bottomed at $2.2 billion in Q3 2022.
• The 5-year median for Current Assets is $2.5 billion (2023), against an average of $2.5 billion.
• Across the five-year window, Current Assets dropped 10.98% in 2024 and gained 21.41% in 2026, its largest moves.
• Year by year, Current Assets stood at $2.2 billion in 2022, then climbed by 19.94% to $2.6 billion in 2023, then slipped by 0.82% to $2.6 billion in 2024, then advanced by 14.13% to $3.0 billion in 2025, then declined by 1.8% to $2.9 billion in 2026.
• Per Business Quant, the three latest IONS Current Assets figures stand at $2.9 billion (Q1 2026), $3.0 billion (Q4 2025), and $2.5 billion (Q3 2025).